Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Physiol Res ; 63(Suppl 4): S601-12, 2014.
Article in English | MEDLINE | ID: mdl-25669691

ABSTRACT

Several pre-clinical and clinical studies have demonstrated zoledronic acid (Zol), which regulates the mevalonate pathway, has efficient anti-cancer effects. Zol can also induce autophagy. The aim of this study is to add new understanding to the mechanism of autophagy induction by Zol. LC3B-II, the marker for autophagy was increased by Zol treatment in breast cancer cells. Autophagosomes induced by Zol were visualized and quantified in both transient (pDendra2-hLC3) and stable MCF-7-GFP-LC3 cell lines. Acidic vesicular organelles were quantified using acridine orange. Zol induced a dose and time dependent autophagy. Treatment of Zol increased oxidative stress in MCF-7 cells, which was reversed by GGOH or anti-oxidants. On the other hand, treatment with GGOH or anti-oxidants resulted in decreased levels of LC3B-II. Further, the induced autophagy was irreversible, as the washout of Zol after 2 h or 24 h resulted in similar levels of autophagy, as induced by continuous treatment after 72 h. Thus, it can be summarized that Zol can induce a dose dependent but irreversible autophagy, by its effect on the mevalonate pathway and oxidative stress. This study adds to the understanding of the mechanism of action of Zol, and that it can induce autophagy at clinically relevant shorter exposure times in cancer cells.


Subject(s)
Autophagy/drug effects , Bone Density Conservation Agents/therapeutic use , Breast Neoplasms/drug therapy , Diphosphonates/therapeutic use , Imidazoles/therapeutic use , Oxidative Stress/drug effects , Bone Density Conservation Agents/pharmacology , Breast Neoplasms/metabolism , Diphosphonates/pharmacology , Humans , Imidazoles/pharmacology , MCF-7 Cells , Mevalonic Acid/metabolism , Zoledronic Acid
2.
Curr Pharm Des ; 16(27): 2970-80, 2010.
Article in English | MEDLINE | ID: mdl-20722618

ABSTRACT

Bisphosphonates are a class of drugs developed over the past three decades for the treatment of metabolic bone diseases with high bone turnover, such as Paget's disease, tumor associated osteolysis and osteoporosis. The exceptional pharmacokinetic profile of bisphosphonates makes them very suitable and safe drugs for the treatment of bone diseases, because, by conventional administration, osseous tissue and bone resorbing osteoclasts are the targets for these drugs as a result of the very high affinity of bisphosphonates for bone mineral. Several recent studies have demonstrated, however, that bisphosphonates decrease tumor burden in bone in rodent models of myeloma and metastatic bone disease, with suggestions of antitumor effects also in patients. Although decreased tumor burden could be a consequence of inhibition of bone resorption, there is increasing evidence that bisphosphonates might also have direct effects on tumor cell in vivo, since effects on tumors outside of skeleton or at doses not inhibiting bone resorption have been reported. Recent studies also suggest that bisphosphonates have inhibitory effect also on endothelial cell function and angiogenesis in tumor tissue. These findings suggest that the target cells for bisphosphonates as well as their molecular mechanism of action may be more diverse and complex than realized so far. This review highlights the main methodologies used to monitor the action of BPs in vitro cell models, with a special emphasis on the detection of BP-induced ATP-analoques by mass spectrometry. In addition, cell death monitoring, immunomodulatory effects and inhibition of growth/proliferation are described.


Subject(s)
Bone Density Conservation Agents/metabolism , Bone Density Conservation Agents/pharmacology , Diphosphonates/metabolism , Diphosphonates/pharmacology , Endothelial Cells/drug effects , Macrophages/drug effects , Neoplasms/drug therapy , Adenosine Triphosphate/analogs & derivatives , Animals , Apoptosis/drug effects , Bone Density Conservation Agents/chemistry , Cell Line , Cell Line, Transformed , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Diphosphonates/chemistry , Drug Design , Drug Screening Assays, Antitumor , Endothelial Cells/metabolism , Humans , Immunologic Factors/chemistry , Immunologic Factors/metabolism , Immunologic Factors/pharmacology , Macrophages/metabolism , Neoplasms/metabolism , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/metabolism , Organophosphorus Compounds/chemistry , Organophosphorus Compounds/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...